Hematologic Malignancy Center Faculty / Medical Staff >

At the Hematologic Malignancy Center, specialists come together from the Division of Hematology and Oncology, the Department of Laboratory Medicine and Genetics, the Department of Pathology, and the Department of Radiation Oncology and provide the best possible and most recent treatment for hematologic malignancy like lymphoma and multiple myeloma. Our goal is to become the best hematologic malignancy center in Asia both for our patients and colleagues by offering the most appropriate treatment and continuing cutting-edge clinical and basic research.

Major areas of treatment / Clinics

Acute and chronic leukemia, anemia aplastic, Hodgkin's disease, non-Hodgkin's lymphoma, myelodysplastic syndrome, multiple myeloma, etc.

Strong points

  • The Center is developing new treatment methods including cytotherapy agents and participating in multinational clinical studies in various phases to introduce the latest medicines to Korea.
  • We guarantee the best patient care thanks to our multi-disciplinary treatment and diagnosis approach. The Division of Hematologic Malignancy Center focuses on the best possible care and research including new drug clinical trials, while the Department of Radiation Oncology is in charge of whole-body irradiation for stem cell transplantation and preventive whole-brain radiotherapies. The Department of Laboratory Medicine and Genetics works on lab tests such as bone marrow examination, chromosome analysis, FISH, and flow cytometry, and the Department of Pathology makes a diagnosis using the latest technology of immunopathology and molecular pathology.
  • The best nursing service is provided by our skilled inpatient and outpatient nurses, oncology nurse practitioners, transplantation coordinators, and research nurses.

Diagnostic tests

Basic blood testing, bone marrow examination, lymph node examination, CT, MRI, PET-CT, etc.

Latest treatment methods

  • Diverse and latest chemotherapies
  • Hematopoietic stem cell transplantation: allogeneic, autologous, cord blood, or mini
  • Immunotherapeutic and cytotherapeutic agents
  • New drug clinical trials

Recent trends in clinical research

We perform the best possible treatment and research including new drug clinical trials for hematologic malignancy. We are currently conducting a global multi-center alemtuzumab clinical study to apply it to mini-transplantation and minimize the risk of graft-versus-host diseases among acute myelogenous leukemia and myelodysplastic syndrome patients over 50. Also, we are applying dose-intensified chemotherapy to acute lymphoblastic leukemia as part of a domestic multi-center clinical study.

To treat chronic myelogenous leukemia, we are using both first- and second-generation Gleevec as a primary therapy, following global guidelines. At the same time, we are conducting global multi-center clinical trials to improve the therapy efficacy. Among them are comparison of Gleevec to nilotinib and radotinib and application of dasatinib depending on early molecular biological reactions to three-month Gleevec administration.

In case of multiple myeloma, the Center conducts international multi-center clinical trials of new drugs including Velcade and performs the latest stem cell transplantation such as autologous and mini-allogeneic stem cell transplantation. For patients with relapsing lymphoma, we clinically research new drugs and antibody therapies.

Departments List

Patients' Rights and Responsibilities

Patients' Rights

1. Right to receive medical care

Patients have the right to receive proper medical and nursing services for their Health Protection and Promotion and they will not be discriminated for gender, age, religion, status, nationality, language, race, or physical/mental/financial circumstances nor be violated of their health. Medical team may not deny medical care without justifiable reason.

2. Right to be informed & autonomous decision

Patients have the right to receive be well-informed and to inquire in detail about the treating physician’s specialty, status of their disease, purpose of the treatment, treatment plan, method, expected results and side effects of the treatment, discharge plan, medical cost, whether or not they are a subject to medical research, organ transplant/donation and etc, and to decide whether to give consent. Patients may stop or deny specific treatment or planned medical care within the ethical guideline and may decide on an alternative treatment.

3. Right to have confidentiality

Patients will not be violated of their rights to confidentiality regarding their physical/health status and privacy. Medical team and facility may not reveal or announce patient’s confidential information, including personal information, unless patient has gives consent or specified in the law, such as criminal investigation.

4. Right to request for consultation and mediation

Patients may request for consultation and mediation from an internal or external agency (Korea Consumer Agency, Korea Medical Dispute Mediation and Arbitration Agency) in the event of any medical dispute.

5. Right to be respected of values or beliefs

Patients will not be discriminated for their culture, religious values or beliefs, and their rights will not be violated.

6. Right to be physically protected and to have stability of mind and bod

Patients have the right to be protected from possible danger in the hospital and to have the stability of mind and body.


1. Responsible to trust and respect the medical team

Patients must accurately inform the medical team of their health condition, trust and respect the medical team’s treatment plan. Patients may be responsible for consequences which results from not following the instruction.

2. Responsible to not use dishonest method for medical treatment

Patients must reveal their identity before receiving any medical care and must not use false or dishonest method, such as receiving medical case under disguised ownership.

3. Responsible to abide by all hospital regulations

Patients must abide by all hospital regulations, respect hospital staff and other patients, and earnestly fulfill the financial obligation to the hospital.